• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

文献计量分析揭示鼻咽癌免疫治疗的研究热点和趋势。

Bibliometric analysis reveals the research hotspots and trends of nasopharyngeal carcinoma immunotherapy.

机构信息

Institute of Oncology, Guangxi Academy of Medical Sciences, Nanning, Guangxi, China.

Department of Otolaryngology & Head and Neck, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.

出版信息

Hum Vaccin Immunother. 2024 Dec 31;20(1):2360341. doi: 10.1080/21645515.2024.2360341. Epub 2024 Jul 21.

DOI:10.1080/21645515.2024.2360341
PMID:39034441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11789730/
Abstract

Immunotherapy is a promising strategy for nasopharyngeal carcinoma (NPC), a common and aggressive malignancy with poor prognosis. However, the literature lacks a comprehensive and objective overview of the current research status and trends of immunotherapy-related fields in NPC. We performed a bibliometric analysis of 513 original articles and reviews in English on immunotherapy for NPC from the Web of Science Core Collection database, using CiteSpace and Bibliometrix software tools. We visualized the development trend of publications, the distribution of countries/regions, the co-occurrence of keywords, the collaboration and citation of authors, the citation of journals, the evolution of topics, and the thematic map. We found that the publication volume increased sharply after 2017, with China as the main contributor and leader, the US as an important partner, and the Netherlands as a potential innovator. The research focused on immune checkpoint inhibitors and cell therapy, which were also the hotspots of clinical trials. Tumor microenvironment, immune infiltration, multicenter studies, and novel immunotherapy were the frontier topics and the key challenges for future research. CD137l-DC, lymphoma, and chimeric antigen receptor were emerging topics with good prospects. Our study provides a valuable insight into the research status and trends of immunotherapy for NPC, which may guide future research directions and clinical applications.

摘要

免疫疗法是一种有前途的治疗鼻咽癌(NPC)的策略,NPC 是一种常见且具有侵袭性的恶性肿瘤,预后较差。然而,文献中缺乏对 NPC 免疫治疗相关领域当前研究现状和趋势的全面、客观的综述。我们使用 CiteSpace 和 Bibliometrix 软件工具,对来自 Web of Science Core Collection 数据库的 513 篇英文免疫治疗 NPC 的原始文章和综述进行了文献计量学分析。我们可视化了出版物的发展趋势、国家/地区的分布、关键词的共现、作者的合作与引用、期刊的引用、主题的演变和主题地图。我们发现,2017 年后,出版物数量急剧增加,中国是主要贡献者和领导者,美国是重要合作伙伴,荷兰是潜在的创新者。研究集中在免疫检查点抑制剂和细胞治疗上,这也是临床试验的热点。肿瘤微环境、免疫浸润、多中心研究和新型免疫疗法是前沿课题,也是未来研究的关键挑战。CD137l-DC、淋巴瘤和嵌合抗原受体是具有良好前景的新兴课题。我们的研究提供了对 NPC 免疫治疗研究现状和趋势的有价值的见解,可能为未来的研究方向和临床应用提供指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecae/11789730/b8d7fdb78577/KHVI_A_2360341_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecae/11789730/df814eb5d960/KHVI_A_2360341_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecae/11789730/dd1851ea7a53/KHVI_A_2360341_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecae/11789730/592f6d36134c/KHVI_A_2360341_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecae/11789730/9d7d7ac81869/KHVI_A_2360341_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecae/11789730/2d83eaf06bec/KHVI_A_2360341_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecae/11789730/017d5aad5d9a/KHVI_A_2360341_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecae/11789730/b8d7fdb78577/KHVI_A_2360341_F0007_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecae/11789730/df814eb5d960/KHVI_A_2360341_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecae/11789730/dd1851ea7a53/KHVI_A_2360341_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecae/11789730/592f6d36134c/KHVI_A_2360341_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecae/11789730/9d7d7ac81869/KHVI_A_2360341_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecae/11789730/2d83eaf06bec/KHVI_A_2360341_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecae/11789730/017d5aad5d9a/KHVI_A_2360341_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecae/11789730/b8d7fdb78577/KHVI_A_2360341_F0007_OC.jpg

相似文献

1
Bibliometric analysis reveals the research hotspots and trends of nasopharyngeal carcinoma immunotherapy.文献计量分析揭示鼻咽癌免疫治疗的研究热点和趋势。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2360341. doi: 10.1080/21645515.2024.2360341. Epub 2024 Jul 21.
2
A bibliometric study of the nasopharyngeal cancer immunotherapy knowledge map.基于文献计量学的鼻咽癌免疫治疗知识图谱研究
Medicine (Baltimore). 2024 Apr 19;103(16):e37763. doi: 10.1097/MD.0000000000037763.
3
Global research trends and focus on immunotherapy for endometrial cancer: a comprehensive bibliometric insight and visualization analysis (2012-2024).子宫内膜癌免疫治疗的全球研究趋势与重点:一项全面的文献计量洞察与可视化分析(2012 - 2024年)
Front Immunol. 2025 Apr 8;16:1571800. doi: 10.3389/fimmu.2025.1571800. eCollection 2025.
4
Current perspectives and trends of CD39-CD73-eAdo/A2aR research in tumor microenvironment: a bibliometric analysis.肿瘤微环境中 CD39-CD73-eAdo/A2aR 研究的现状和趋势:文献计量学分析。
Front Immunol. 2024 Aug 12;15:1427380. doi: 10.3389/fimmu.2024.1427380. eCollection 2024.
5
Trends in the immunotherapy for glioblastoma: A two-decade bibliometric analysis.胶质母细胞瘤免疫治疗的趋势:二十年文献计量分析
Hum Vaccin Immunother. 2025 Dec;21(1):2466299. doi: 10.1080/21645515.2025.2466299. Epub 2025 Feb 14.
6
Emerging trends and research foci of oncolytic virotherapy for central nervous system tumors: A bibliometric study.溶瘤病毒治疗中枢神经系统肿瘤的研究热点和趋势:文献计量学研究。
Front Immunol. 2022 Sep 6;13:975695. doi: 10.3389/fimmu.2022.975695. eCollection 2022.
7
Global trends in tertiary lymphoid structures: a bibliometric analysis from 2014 to 2023.三级淋巴结构的全球趋势:2014年至2023年的文献计量分析
Front Immunol. 2024 Nov 15;15:1475062. doi: 10.3389/fimmu.2024.1475062. eCollection 2024.
8
Knowledge mapping of immunotherapy for breast cancer: A bibliometric analysis from 2013 to 2022.免疫治疗乳腺癌的知识图谱:2013 年至 2022 年的文献计量分析。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2335728. doi: 10.1080/21645515.2024.2335728. Epub 2024 Apr 2.
9
Emerging insights into thyroid cancer from immunotherapy perspective: A bibliometric analysis.从免疫治疗角度看甲状腺癌的新见解:文献计量分析。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2403170. doi: 10.1080/21645515.2024.2403170. Epub 2024 Sep 18.
10
Global research trends in immunotherapy for glioma: a comprehensive visualization and bibliometric analysis.全球胶质母细胞瘤免疫治疗研究趋势:全面可视化和文献计量分析。
Front Endocrinol (Lausanne). 2023 Oct 5;14:1273634. doi: 10.3389/fendo.2023.1273634. eCollection 2023.

引用本文的文献

1
Comment on "Bibliometric analysis reveals the research hotspots and trends of nasopharyngeal carcinoma immunotherapy".对《文献计量分析揭示鼻咽癌免疫治疗的研究热点与趋势》的评论
Hum Vaccin Immunother. 2024 Dec 31;20(1):2411121. doi: 10.1080/21645515.2024.2411121. Epub 2024 Oct 22.
2
Comment on "Bibliometric analysis reveals the research hotspots and trends of nasopharyngeal carcinoma immunotherapy".关于《文献计量分析揭示鼻咽癌免疫治疗的研究热点与趋势》的评论
Hum Vaccin Immunother. 2024 Dec 31;20(1):2393485. doi: 10.1080/21645515.2024.2393485. Epub 2024 Aug 30.

本文引用的文献

1
Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma - A Systematic Review and Meta-analysis.细胞免疫疗法治疗复发性或转移性鼻咽癌的疗效和安全性的系统评价和荟萃分析。
Oral Oncol. 2024 May;152:106786. doi: 10.1016/j.oraloncology.2024.106786. Epub 2024 Apr 13.
2
FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers.美国食品药品监督管理局批准了首个肿瘤浸润淋巴细胞(TIL)疗法,增强了实体癌细胞疗法的希望。
Nat Rev Drug Discov. 2024 Apr;23(4):238. doi: 10.1038/d41573-024-00035-1.
3
A bibliometric analysis of m6A methylation in viral infection from 2000 to 2022.
2000 年至 2022 年病毒感染中 m6A 甲基化的文献计量学分析。
Virol J. 2024 Jan 18;21(1):20. doi: 10.1186/s12985-024-02294-1.
4
Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials.免疫检查点抑制剂联合化疗作为复发性或转移性鼻咽癌一线治疗的疗效和安全性:一项随机对照试验的网络荟萃分析。
Ann Pharmacother. 2024 Apr;58(4):349-359. doi: 10.1177/10600280231188171. Epub 2023 Jul 24.
5
First-line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta-analysis and cost-effectiveness analysis.一线免疫治疗联合方案治疗复发性或转移性鼻咽癌:更新的网络荟萃分析和成本效益分析。
Head Neck. 2023 Sep;45(9):2246-2258. doi: 10.1002/hed.27452. Epub 2023 Jul 12.
6
Immunotherapy in the First-Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis.免疫疗法在晚期鼻咽癌一线治疗中的应用:系统评价和荟萃分析。
Laryngoscope. 2024 Jan;134(1):7-17. doi: 10.1002/lary.30754. Epub 2023 May 25.
7
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309).替雷利珠单抗联合化疗作为复发或转移性鼻咽癌的一线治疗:一项多中心 III 期试验(RATIONALE-309)。
Cancer Cell. 2023 Jun 12;41(6):1061-1072.e4. doi: 10.1016/j.ccell.2023.04.014. Epub 2023 May 18.
8
Active recruitment of anti-PD-1-conjugated platelets through tumor-selective thrombosis for enhanced anticancer immunotherapy.通过肿瘤选择性血栓形成主动募集抗 PD-1 偶联血小板以增强抗癌免疫治疗。
Sci Adv. 2023 Mar 29;9(13):eadf6854. doi: 10.1126/sciadv.adf6854.
9
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers.癌症相关成纤维细胞(CAFs)在实体瘤抗 PD-1/PD-L1 免疫治疗中的作用。
Mol Cancer. 2023 Feb 10;22(1):29. doi: 10.1186/s12943-023-01731-z.
10
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.实体瘤治疗时代的嵌合抗原受体细胞治疗:当前的挑战和新出现的治疗进展。
Mol Cancer. 2023 Jan 30;22(1):20. doi: 10.1186/s12943-023-01723-z.